BIIB · News · 20260806N

Product / Drug Pipeline Progress

BIOGEN INC. · 2026-08-06 · Importance 37 · Surprise 42

Denali Therapeutics discontinued the Parkinson’s disease program BIIB122/DNL151 after its Phase 2b study failed to meet endpoints. BIIB122/DNL151 was being developed in collaboration with Biogen, making the discontinuation a setback for Biogen’s neurodegenerative-disease pipeline. The program decision contrasts with Denali’s commercial launch of AVLAYAH for Hunter syndrome, but the reported item provides no further detail on Biogen’s replacement development plans.

Key facts